High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.
Kontou-Fili
K
K
Chief Allergology Department, Euroclinic Hospital, Athens, 8 Fidippidou st., Athens 11526, Hellas, Greece. kontoufk@otenet.gr
D000707:Anaphylaxis / Q000188:drug therapy* / Q000209:etiology; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007114:Immunization / Q000379:methods*; D007167:Immunotherapy / Q000379:methods; D007279:Injections, Subcutaneous; D007299:Insect Bites and Stings / Q000276:immunology*; D008297:Male; D008415:Mastocytosis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D000069444:Omalizumab; D012008:Recurrence; D018570:Risk Assessment; D012882:Skin Tests; D016896:Treatment Outcome
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab